More Canadian kids being diagnosed with inflammatory bowel disease study CTV...
CTV NewsMore Canadian kids being diagnosed with inflammatory bowel disease studyCTV NewsCanada has one of the highest rates of pediatric inflammatory bowel disease in the world and the number of young...
View ArticleHigh Response and Remission Rates in AntiTNF Nave Patients Treated with Qu...
VANCOUVER British Columbia April 19 2017 GLOBE NEWSWIRE Qu Biologics Inc. a biopharmaceutical company developing Site Specific Immunomodulators SSIs a unique platform of immunotherapies designed to...
View ArticleCrohn's & Colitis Foundation Welcomes New National Trustees Seven Join...
NEW YORK April 19 2017 PRNewswireUSNewswire The Crohn's & Colitis Foundation the Foundation is pleased to announce seven new members of its National Board of Trustees which oversees the...
View ArticleDrug discovery company Arena Pharmaceuticals nets $64.9mm in FOPO
Arena Pharmaceuticals Inc. small molecule drugs across various therapy areas netted $64.9mm in a followon public offering of 60mm common shares at $1.15. The company will use the proceeds from the...
View ArticleHigh Response And Remission Rates In AntiTnfa Nave Patients Treated With Qu...
Life Sciences Jobs ...
View ArticleHigh Response And Remission Rates In AntiTnfa Nave Patients Treated With Qu...
Life Sciences Jobs ...
View ArticleAevi Genomic Medicine Presents Updated Results from SAGA Trial of AEVI001 at...
PHILADELPHIA PA Marketwired 042017 Novel genetic mutations predictive of response to AEVI001 found in approximately 10 of pediatric ADHD patients New results clarify a path forward for the continued...
View ArticleImmune Pharmaceuticals Signs Letter of Intent with Pint Pharma Regarding...
NEW YORK April 20 2017 PRNewswire Immune Pharmaceuticals Inc. NASDAQ IMNP "Immune" or "Immune Pharma" announced today that it has entered into a letter of intent with Pint Pharma GmnH a pharmaceutical...
View ArticleTikun Olam the World's Original Medical Cannabis Company Announces US...
NEW YORK April 20 2017 PRNewswire The United States will experience a wellness revolution through a new line of clinicallyproven proprietary cannabis products from Tikun Olam a premier science based...
View ArticleImedex and American College of Gastroenterology Announce Collaboration for...
Advances In Inflammatory Bowels Diseases 2017 the most important IBD clinical meeting this year is now endorsed by the American College of Gastroenterology. Imedex AIBD&39;s organizer and...
View ArticleProtagonist Therapeutics Announces PTG200 Data Accepted for Oral Presentation...
MILPITAS Calif. April 20 2017 PRNewswire Protagonist Therapeutics Inc. Nasdaq PTGX today announced that preclinical research findings on PTG200 the company's oral peptide IL23 receptor antagonist has...
View ArticleValeant's Patient Access And Pricing Committee Announces Pricing For SILIQ...
LAVAL Quebec April 21 2017 PRNewswire Valeant Pharmaceuticals International Inc. NYSE VRX and TSX VRX today announced that following the evaluation and approval of its Patient Access and Pricing...
View ArticleBiosimilars of certolizumab pegol
Certolizumab pegol is a monoclonal antibody directed against tumour necrosis factoralfa TNF. More precisely it is a PEGylated Fab fragment of a humanized TNF inhibitor monoclonal antibody. It is...
View ArticleColitis Pipeline Review H1 2017 Updated 28022017 Prices from USD $2000
Colitis Pipeline Review H1 2017SummaryGlobal Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Colitis Pipeline Review H1 2017 provides an overview of the Colitis...
View ArticleCovance to Expand LargeMolecule Development Capabilities in the UK
Covance Drug Development continues to invest in precision medicine with expansion into laboratory space at York facility Laboratory Corporation of America Holdings LabCorp NYSE LH a leading global...
View ArticleArena Pharmaceuticals Announces Completion of Public Offering of Common Stock...
SAN DIEGO April 21 2017 PRNewswire Arena Pharmaceuticals Inc. NASDAQ ARNA today announced the completion of its previously announced underwritten public offering of 69000000 shares of its common stock...
View ArticleDrug discovery company Arena Pharmaceuticals nets $74.6mm in FOPO
Arena Pharmaceuticals Inc. small molecule drugs across various therapy areas netted $74.6mm in a followon public offering of 69mm common shares including full exercise of the 9mm overallotment option...
View ArticleFDA approves biosimilar for infliximab
Today the FDA has approved Merck and Samsung Bioepis infliximab biosimilar for injection which is known as infliximababda Renflexis. It will maintain the same indications as the reference...
View ArticleCrohn's Colitis Foundation Inc Pharmaceuticals Healthcare Deals and Alliances...
SummaryCrohn's Colitis Foundation Inc CCF is a nonprofit organization which focuses on providing treatments for crohn's disease and ulcerative colitis. The organization funds studies at medical...
View ArticleSamsung Bioepis Obtains First Drug Approval in the United States as the U.S....
Samsung Bioepis Co. Ltd. today announced that the U.S. Food and Drug Administration FDA has approved RENFLEXIS infliximababda a biosimilar referencing RemicadeÂi infliximab across all eligible...
View Article